Euroapi, Sanofi-spunoff standalone active pharmaceutical ingredient manufacturing business, has heavily rowed back its financial expectations for 2023 and hit pause on its longer-term targets, citing several external challenges as it announced plans to launch a fresh strategic review to adapt to the new environment it sees.
The French firm’s announcement spooked investors, sending Euroapi shares crashing by almost 60% from more than €12 ($12.64) per share...








